BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...R&D co-investment areas of expertise. CBC has been a key investor in cross-border licensing company Everest Medicines Ltd....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...LianBio, a $310 million series C for Everest Medicines Ltd....
BioCentury | Oct 20, 2020
Politics, Policy & Law

FDA’s future & China Summit Preview

...roundtable, which features leaders of three MNCs and Everest Medicines Ltd....
...really hot companies on that session including Everest Medicines...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

...and Western biotechs have delivered as much as $40 million up front.A 2019 deal giving Everest Medicines Ltd....
BioCentury | Oct 17, 2020
Finance

Date Bytes: Everest among five largest IPOs on Hong Kong’s biotech chapter

...by proceeds were all late-stage, with lead programs in registration, approved or on the market. Amanda Micklus Everest Medicines Ltd. IPOs HKEX...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...off one of the largest IPOs to date on the Hong Kong stock exchange’s biotech chapter:Everest Medicines Ltd....
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...of early breast cancer.Everest rises after Hong Kong IPOIn its first day of trading Friday, Everest Medicines Ltd....
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...a share issue balanced between the offering’s local and international components.Cross-border in-licensing and development company Everest Medicines Ltd....
...The deal valued Everest at more than $2 billion.In its first day of trading Friday, Everest Medicines Ltd....
...listed elsewhere and thus were not conducting IPOs on the biotech chapter. Paul Bonanos HRS7-SN-38, sacituzumab govitecan (IMMU-132) Everest Medicines Ltd. CHS2020...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...begin building its commercial team. The company then hired COO Wende Chen, an executive with experience at Everest Medicines Ltd....
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...royalties on Trodelvy’s sales. It also granted Everest Medicines Ltd....
Items per page:
1 - 10 of 38
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...R&D co-investment areas of expertise. CBC has been a key investor in cross-border licensing company Everest Medicines Ltd....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...LianBio, a $310 million series C for Everest Medicines Ltd....
BioCentury | Oct 20, 2020
Politics, Policy & Law

FDA’s future & China Summit Preview

...roundtable, which features leaders of three MNCs and Everest Medicines Ltd....
...really hot companies on that session including Everest Medicines...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

...and Western biotechs have delivered as much as $40 million up front.A 2019 deal giving Everest Medicines Ltd....
BioCentury | Oct 17, 2020
Finance

Date Bytes: Everest among five largest IPOs on Hong Kong’s biotech chapter

...by proceeds were all late-stage, with lead programs in registration, approved or on the market. Amanda Micklus Everest Medicines Ltd. IPOs HKEX...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...off one of the largest IPOs to date on the Hong Kong stock exchange’s biotech chapter:Everest Medicines Ltd....
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...of early breast cancer.Everest rises after Hong Kong IPOIn its first day of trading Friday, Everest Medicines Ltd....
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...a share issue balanced between the offering’s local and international components.Cross-border in-licensing and development company Everest Medicines Ltd....
...The deal valued Everest at more than $2 billion.In its first day of trading Friday, Everest Medicines Ltd....
...listed elsewhere and thus were not conducting IPOs on the biotech chapter. Paul Bonanos HRS7-SN-38, sacituzumab govitecan (IMMU-132) Everest Medicines Ltd. CHS2020...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...begin building its commercial team. The company then hired COO Wende Chen, an executive with experience at Everest Medicines Ltd....
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...royalties on Trodelvy’s sales. It also granted Everest Medicines Ltd....
Items per page:
1 - 10 of 38